PMID: 7543822Jul 1, 1995Paper

In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody

Cancer Immunology, Immunotherapy : CII
G A PieterszJ A Trapani

Abstract

Mouse monoclonal antibodies to CD19 detect an antigenic determinant expressed exclusively on the surface of B lymphocytes, and have previously been shown to be potentially useful therapeutic reagents for human B cell lymphoma. We report the production and characterization of a mouse/human chimeric antibody, cCD19, with potent in vivo antitumour activity. The genes encoding the variable domains for heavy (VH) and light (VL) chains were subcloned into eukaryotic expression vectors containing human constant region genes (IgG1 and kappa), and co-transfected into non-secreting Sp2/0 mouse myeloma cells. Intraperitoneal administration of cCD19 produced inhibition of growth of subcutaneous CD19+ Sultan human B lymphoma tumours in scid/scid mice. When the antibody was administered 18 and 20 days after subcutaneous tumour inoculation, an approximately 30% reduction in tumour size was noted by day 29. cCD19 faithfully mimicked the in vitro binding characteristics of mCD19 as (a) the chimeric antibody was shown by flow cytometry to bind exclusively to cell lines that expressed CD19, (b) cCD19 was able to inhibit the binding of mCD19 on CD19+ cells completely and (c) the affinity of binding of the two antibodies was not significantly diffe...Continue Reading

References

Apr 22, 1992·International Journal of Cancer. Journal International Du Cancer·P RivaG Franceschi
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·R HandgretingerD Niethammer
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·A HekmanC J Melief
Dec 1, 1991·Immunology and Cell Biology·H ZolaY Kurosawa
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E GoodmanK E Hellström
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O W PressK A Krohn
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R OrlandiG Winter
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Mar 24, 1988·Nature·L RiechmannG Winter
Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·Y Haruta, B K Seon
Aug 12, 1993·The New England Journal of Medicine·M S KaminskiG M Butchko
Aug 1, 1993·Cancer Immunology, Immunotherapy : CII·A J RowlandI F McKenzie
Feb 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·L M WeinerD G Haller
Aug 1, 1993·British Journal of Cancer·V HirdA A Epenetos

❮ Previous
Next ❯

Citations

Jan 5, 2002·Veterinary Immunology and Immunopathology·Sylvain De GuiseDavid A Ferrick
Oct 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Norihito YazawaThomas F Tedder
Aug 1, 2007·Cancer Immunology, Immunotherapy : CII·Julia StieglmaierWijnand Helfrich
Jul 5, 2005·Expert Opinion on Investigational Drugs·S MukerjeeM C Glassy
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·T J Walsh, A H Groll
Mar 15, 2006·Journal of Immunotherapy·Karin BarbinGeorg H Fey
Jun 22, 2005·International Immunology·Jun YanMark J Mamula
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Camelia I SpiridonEllen S Vitetta
Jan 12, 2005·Protein Expression and Purification·Dipankar DasMavanur R Suresh

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.